Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 USD | -0.59% |
|
-8.70% | -11.58% |
06/06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
05/06 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
Sales 2024 * | 8L 6.26Cr | Sales 2025 * | 8L 6.26Cr | Capitalization | 14Cr 1.13TCr |
---|---|---|---|---|---|
Net income 2024 * | -14Cr -1.19TCr | Net income 2025 * | -15Cr -1.22TCr | EV / Sales 2024 * | 181 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 181 x |
P/E ratio 2024 * |
-1.17
x | P/E ratio 2025 * |
-1.55
x | Employees | 220 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.84% |
Latest transcript on I-Mab
1 day | -0.59% | ||
1 week | -8.70% | ||
Current month | +1.20% | ||
1 month | -4.00% | ||
3 months | -10.16% | ||
6 months | +8.39% | ||
Current year | -11.58% |
![Extreme 1.67](/images/extremecours_fleche.png)
![Extreme 1.51](/images/extremecours_fleche.png)
![Extreme 1.48](/images/extremecours_fleche.png)
![Extreme 1.16](/images/extremecours_fleche.png)
![Extreme 1.16](/images/extremecours_fleche.png)
![Extreme 1.16](/images/extremecours_fleche.png)
![Extreme 1.16](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Rajkumar Kannan
CEO | Chief Executive Officer | 61 | 22/23/22 |
Jerry Wang
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yi Fei Zhu
PRN | Corporate Officer/Principal | 55 | 10/20/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chia Hung Yang
BRD | Director/Board Member | 61 | 01/20/01 |
Pamela Klein
CHM | Chairman | 63 | 01/20/01 |
Shuai Chen
BRD | Director/Board Member | 50 | 01/23/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.79% | 96 M€ | -.--% | - | |
0.57% | 4 M€ | -27.92% | ||
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 4 M€ | -4.41% | - |
Date | Price | Change | Volume |
---|---|---|---|
21/24/21 | 1.68 | -0.59% | 95,766 |
20/24/20 | 1.69 | -4.52% | 187,773 |
18/24/18 | 1.77 | -2.75% | 150,203 |
17/24/17 | 1.82 | -1.09% | 145,856 |
Delayed Quote Nasdaq, June 22, 2024 at 01:30 am IST
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.58% | 14Cr | |
+51.63% | 80TCr | |
+40.90% | 63TCr | |
-5.10% | 36TCr | |
+19.90% | 33TCr | |
+9.95% | 30TCr | |
+17.32% | 24TCr | |
+3.84% | 23TCr | |
+12.55% | 21TCr | |
+6.99% | 17TCr |
- Stock Market
- Equities
- IMAB Stock